N-cyclooctyl-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine | 252853-21-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: N-cyclooctyl-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
• CAS: 252853-21-7
• 化学式: C₁₅H₂₂N₄
• 分子量: 258.366
• InChiKey: RKLMARNVJRXNBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  44.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  环辛基甲胺 、 4-氯吡咯并嘧啶 以 叔丁醇 为溶剂， 生成 N-cyclooctyl-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  参考文献：
  名称：

  Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

  摘要：

  There is a critical need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis. Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions. Blockade of the JAK1/JAK3-STAT pathway with a small molecule was anticipated to provide therapeutic immunosuppression/immunomodulation. The Pfizer compound library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by CP-352,664 (2a). Synthetic analogues of 2a were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay. Select compounds were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis. Optimization within this chemical series led to identification of CP-690,550 1, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.

  DOI：

  10.1021/jm1004286

文献信息

• Pyrrolo[2,3-d]pyrimidine compounds
  申请人：——

  公开号：US20020019526A1

  公开（公告）日：2002-02-14

  A compound of the formula 1 wherein R 1 , R 2 and R 3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.

  一种化合物的结构式，其中R1、R2和R3如上所定义，它们是蛋白酪氨酸激酶的抑制剂，如Janus激酶3，因此可作为免疫抑制剂用于器官移植、狼疮、多发性硬化、类风湿性关节炎、牛皮癣、1型糖尿病和糖尿病并发症、癌症、哮喘、特应性皮炎、自身免疫性甲状腺疾病、溃疡性结肠炎、克罗恩病、阿尔茨海默病、白血病和其他自身免疫疾病的治疗。
• Pyrrolo [2,3-D] pyrimidine compounds
  申请人：Pfizer Inc.

  公开号：US20030212273A1

  公开（公告）日：2003-11-13

  A compound of the formula 1 wherein R 1 , R 2 and R 3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.

  化合物的公式为1，其中R1，R2和R3的定义如上所述，它们是蛋白酪氨酸激酶的抑制剂，例如Janus Kinase 3，并且作为免疫抑制剂用于器官移植，狼疮，多发性硬化症，类风湿性关节炎，牛皮癣，1型糖尿病和糖尿病并发症，癌症，哮喘，特应性皮炎，自身免疫性甲状腺疾病，溃疡性结肠炎，克罗恩病，阿尔茨海默病，白血病和其他自身免疫性疾病的有用治疗方法。
• PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS
  申请人：Pfizer Products Inc.

  公开号：EP1087970B1

  公开（公告）日：2004-04-28
• US6610847B2
  申请人：——

  公开号：US6610847B2

  公开（公告）日：2003-08-26
• US6890929B2
  申请人：——

  公开号：US6890929B2

  公开（公告）日：2005-05-10